T he recent US FDA approval of 2 cancer immunotherapy agents, sipuleucel-T (Provenge) for castrate-resistant metastatic prostate cancer and ipilimumab (Yervoy) for unresectable or metastatic melanoma, has been associated with a resurgence of interest in the field. It has long been known that tumor-infiltrating lymphocytes (TIL) are associated with better prognosis in melanoma 1 and that autologous TIL can be harvested, expanded ex vivo, and reinfused to produce remarkable remissions in selected patients, particularly after prior lymphodepleting treatment. 2 Alternatively, genetic engineering of peripheral blood T cells to encode a novel T-cell receptor can redirect T cells to tumor-associated antigens if native immune responses are insufficient. 3 Furthermore, a different genetic engineering technology can marry the exquisite specificity of antibodies for non-MHC-restricted cell-surface tumorassociated antigens to the potency and replicative potential of T cells. 4 Here, T cells are genetically modified to express a chimeric antigen receptor (CAR), which comprises an antibody-derived ectodomain fused to a T-cell signaling endodomain. In contrast to TIL and transgenic T-cell receptor T cells, the fact that CAR T cells lack MHC restriction enables them to bypass common tumor immune evasion strategies such as loss of MHC class I expression and antigen-processing defects. 5 CAR T cells may also overcome hyporesponsiveness, 6 and the incorporation of one or more costimulatory signaling domains may enhance T-cell expansion and persistence. 7, 8 Clinically meaningful antitumor activity of this approach has been manifest in the use of second-generation CD19-specific CAR T cells to induce complete remissions in leukemia patients. 9, 10 While CAR T cells have not yet been trialed in melanoma patients, preclinical studies have been performed using T cells modified with a retroviral vector to express a third-generation CAR, which is directed against the GD2 disialoganglioside and which incorporates CD28, OX40, and CD3z signaling domains. GD2 is expressed at high levels on tumors of neuroectodermal origin such as neuroblastoma and melanoma and at low levels in normal neural tissues. Compared with GD2-CAR incorporating CD3z alone, CD3z and CD28, or CD3z and OX40, T cells expressing this third-generation GD2-CAR demonstrated superior, albeit antigen-dependent, properties of in vitro expansion and cytokine secretion. 8 Moreover, the GD2-CAR T cells had significant activity in vivo against GD2-expressing melanoma xenografts. 11 In a phase I trial of autologous T cells bearing a firstgeneration GD2-CAR in relapsed and refractory neuroblastoma patients, several tumor regressions were observed 12 and a memory population of CAR T cells persisted in peripheral blood. 13 Now the third-generation GD2-CAR retroviral vector 8 has been further modified to express an inducible caspase-9 suicide gene as a "safety switch" to allow for the targeted removal of adoptively transferred T cells in the case of a severe adverse event. 14 The resulting GD2-iCAR vector is being used for the genetic modification of autologous T cells in the phase I GRAIN trial in advanced neuroblastoma patients (NCT01822652) and in the phase I CARPETS trial in patients with metastatic melanoma (ACTRN12613000198729).
The BRAF and MEK classes of small molecule kinase inhibitors (BRAFi and MEKi) have also recently been US FDA-approved for treatment of unresectable, metastatic V600 BRAF mutant melanoma, which accounts for up to 50% of advanced melanoma cases. These drugs produce prompt tumor regressions in half or more of patients but complete responses are uncommon (r10%), [15] [16] [17] and tumors relapse in most patients. A sound rationale exists for combining immunotherapy and selective BRAF inhibitors, 18 particularly as this class of drugs reportedly has proimmunogenic functions. [19] [20] [21] Consequently, the speed and higher response rates of these kinase inhibitors may provide a therapeutic platform for combinations with immunotherapy agents, which have lower but more durable response rates with a slower onset of action. 22 Although there have been 2 reported investigations of the effect of vemurafenib (Vem) 23, 24 on lymphocytes in vitro, and 1 recent study on the effects of dabrafenib (Dab) or trametinib (Tram), 25 there have been no reports on the effect of any of these drugs on CAR T cells, and no reports that directly compare the effects of the 3 drugs on normal lymphocytes. Given the established place for BRAFi and combined BRAFi/MEKi therapy in the clinical management of metastatic melanoma, we are particularly interested in combining one or both targeted therapies with GD2-specific CAR T cells as a novel therapy. However, first we must ascertain if BRAFi or MEKi therapy adversely affect the function of CAR T cells. In this study, we have therefore investigated the effects of these drugs at a range of concentrations on multiple functions of GD2-iCAR T cells derived from melanoma patients and normal peripheral blood mononuclear cells (PBMC) from healthy volunteers.
MATERIALS AND METHODS
Cell Culture of Tumor Cell Lines, PBMC, and GD2-iCAR PBT Cells LAN-1 were maintained in 1:1 DMEM:F-12 media (Sigma Aldrich, Castle Hill, Australia) supplemented with 10% FBS (Bovogen, East Keilor, Australia) and 1% L-glutamine (IDL, Adelaide, Australia). M238, M238R1, and SKMel-28 were maintained in RPMI supplemented with 10% FBS, 1% L-glutamine, and 1% penicillin/gentamicin (IDL). Peripheral blood samples of 50 mL in heparin were obtained from healthy donors and from melanoma patients with approval from the Royal Adelaide Hospital Human Research Ethics Committee. Within 1 hour of collection, PBMC were purified by density-gradient separation with Lymphoprep (EliTech Group, Braeside, Australia) and cryopreserved before use. After thawing of samples, trypan blue counts were performed to determine viability, with a cut-off of <80% (median viability was 90%). PBMC, GD2-iCAR PBT, and nontransduced controls were cultured in complete RPMI [1:1 Advanced RPMI (Life Technologies, Mulgrave, Australia) and Click's Media (Irvine Scientific, Santa Ana, CA) supplemented with 10% certified FBS (Thermo Scientific, Scoresby, Australia), and 1% L-glutamine (Life Technologies)]. The drugs Vem (PLX4032; SelleckChem, Houston, TX), Dabrafenib (GSK2118436; SelleckChem), and Tram (GSK1120212; SelleckChem) were resuspended at 10 mM in 100% DMSO and stored at À 201C as single-use aliquots, and further diluted in appropriate culture media directly before use in cell culture experiments. For all assays control cells were incubated in the appropriate concentration of DMSO (0.1%-1%) as a vehicle control. For all assays, cells were stimulated with plate-bound 1 mg/mL anti-CD3/ CD28 (Miltenyi Biotech, Sydney, Australia) or 5 mg/mL 1A7 (anti-GD2 CAR antibody, purified in house).
Retroviral Transduction and Expansion of GD2-iCAR PBT
PBMC were activated on anti-CD3 and anti-CD28-coated 24-well plates (Miltenyi Biotech) for 3 days, and feed with 100 U/mL IL-2 (Proleukin) (Prometheus Therapeutics, San Diego, CA) on day 2. On day 3, cells were transferred to retronectin-coated 24-well plates (Promega, Sydney, Australia) and transduced with 1.5 mL or retroviral supernatant (CAGT; BCM, Houston, TX). Cells were then expanded over 10-14 days and transferred to G-Rex culture flasks (Wilson Wolf, Saint Paul, MN) once they reached 50 million cells. After expansion to 500-1000 million cells, cells were washed and cryopreserved in 40% Albumex20 (Red Cross Blood Service, Melbourne, Australia) 40% HBSS (Life Technologies) 10% DMSO using a Cryomed control rate freezer (Thermo Scientific).
ATP Assays
Cell viability was assessed by ATP assay using CellTiterGlo Luminescence Cell Viability Assay (Promega). PBMC and GD2-iCAR PBT were cultured in 96-well plates with or without stimulation for 72 hours in the presence of inhibitor drugs. At 72 hours, 50 mL of cell/media suspension was transferred to a white opaque 96-well plate (Sigma Aldrich) and 50 mL of CellTiterGlo Reagent. Luminescence was analyzed on a FLUOstar Optima plate reader (BMG LabTech, Mornington, Australia).
Flow Cytometry
Cells were analyzed on BDFACSCanto II (BD Biosciences, North Ryde, Australia) and FloJo Software (TreeStar, Ashland, OR). Isotype controls were used in each assay to establish negative gates. All gating strategies and representative data sets as required by the MIATA guidelines are shown in Figure S6 (Supplemental Digital Content 1, http://links.lww.com/JIT/A361).
Surface Molecule Staining
For GD2 CAR expression and immunophenotyping analysis, cells were stained in 50 mL of staining/wash buffer (PBS, 0.01%, sodium azide, 0.5% BSA) with 1A7 (10 mg/ mL) for 30 minutes on ice, washed twice, then stained with anti-mouse PE-conjugated secondary antibody (1:50; BD Biosciences) on ice for 30 minutes, then washed twice and stained with panel A: anti-CD3 FITC, anti-CD8 PECy7, anti-CD45RA-APC, anti-CCR7-bv421, anti-CD4-bv510, and 7AAD or panel B: anti-CD3-FITC, anti-CD16-Pecy7, anti-CD14-APC, anti-CD56-bv421, anti-CD19-bv510, and 7AAD (1:100; BD Biosciences). For viability/activation analysis, cells were cultured for 72 hours in the presence of BRAF or MEK inhibition with or without stimulation, then stained in 50 mL of staining buffer with anti-CD25-APC (BD Biosciences), washed twice, and the incubated in 1 Â Annexin V Binding buffer with AnnexinV-FITC (BD Biosciences) and DAPI (Sigma Aldrich) for 10 minutes at room temperature then analyzed immediately. For proliferation analysis, cells were cultured for 72 hours in the presence of BRAF or MEK inhibition with or without stimulation then fixed in 75% ice cold ETOH for 2 hours at À201C and then washed and stained with anti-CD3-PE, anti-CD8-Pecy7, and anti-Ki67-FITC (BD Biosciences) at 41C for 30 minutes and washed and analyzed immediately.
Intracellular Cytokine Staining and CD107a Staining
Cells were incubated for 48 hours in the presence of BRAF or MEK inhibition without stimulation, then transferred to uncoated or antiCD3/CD28, or 1A7 precoated plates for 6 hours. At the time of transfer antiCD107a-APC (BD Biosciences) was added to the wells, and after 1 hour GolgiStop (BD Biosciences) was added. After stimulation, cells were washed twice and the fix/permed in eBioscience Cytofix/Perm buffer, washed in eBioscience Perm buffer (eBioscience, San Diego, CA) and then incubated for 60 minutes at room temperature with anti-CD3-PE, anti-CD8-Pecy7, and anti-IFNg-FITC (BD Biosciences), and then washed and stored overnight at 41C before analysis.
Phosflow Staining
Cells were cultured for 72 hours in the presence of inhibitor drugs, with or without stimulation, and then were fixed with BD Cytofix buffer and permed with Phosflow Perm Buffer III (BD Biosciences) then washed with staining buffer and stained with anti-CD3 PE, and-CD8-Pecy7 and either panel A anti-pERK1/2-FITC, anti-pAKT-bv421 or panel B anti-pSTAT6-FITCm anti-pSTAT5-bv421 for 60 minutes at room temperature (BD Biosciences) and then washed and analyzed immediately.
Cytokine Bead Array
Cytokine bead arrays were performed using a BD Human Th1/Th2 Cytokine Assay Kit (#551809) according to the manufacturer's instructions (BD Biosciences) Supernatants from cells cultured for 72 hours in the presence of inhibitor drugs, with or without stimulation were collected and stored at -801C before being diluted 1:2 and used in the assay. Results were analyzed by FCAP Array 3.0 Software. Cr/2 million cells (Perkin Elmer, Melbourne, Australia). Cells were cocultured for 6 hours in the presence of inhibitor drugs, then 30 mL supernatant was removed and added to LumaPlates (Perkin Elmer), dried overnight, and analyzed using a TopCount (Perkin Elmer). For cytotoxic T lymphocyte (CTL) assays with PD1 blockade the anti-PD1 monoclonal pembrolizomab (Merck, Sharp, and Dome, Australia) 10 mg/ mL of antibody was included in the cocultures for the 6-hour incubation period. The mean percentage of specific lysis of triplicate wells was calculated as 100Â (experimental releasespontaneous release)/(maximal release-spontaneous release). Raw data can be provided on request.
Cytotoxicity Assays

Statistical Analysis
Data were analyzed using GraphPad Prism Version 6.0d. Single variable data (cell stimulation treatment) were analyzed by 1-way ANOVA and Bonferroni multiple comparison posttests. Two-variable data (cell stimulation treatment and drug treatment) were analyzed by 2-way ANOVA and Bonferroni multiple-comparisons posttests. Significance is represented on graphs as *r05, **r0.01, and ***r0.001.
RESULTS
Retroviral Transduction of Patient PBMC to Generate GD2-specific CAR Peripheral Blood T Cells (GD2-iCAR PBT)
To generate GD2-iCAR PBT, we activated patient PBMC and transduced these cells with a replicationdefective retroviral vector generated at the Center for Cell and Gene Therapy, Baylor College, Houston, TX. The vector encodes a third-generation CAR with CD3z, CD28, and OX40 signaling domains, 8 and an inducible Caspase 9 (iC9) that, upon dimerization with the small molecule drug AP1903, results in a signaling cascade leading to cell death 26 (Fig. 1A) . Three patient PBMC samples were transduced resulting in surface expression of the GD2-iCAR in 55%-70% of cells and the level of GD2-iCAR expression increased upon activation (Fig. 1B) . Furthermore, the GD2-iCAR PBT-mediated specific lysis of the GD2-expressing neuroblastoma cell line, LAN-1, with no killing of autologous PHA-blasts (Fig. 1D ). The 3 CAR T-cell products were >91% CD3 + , and the population comprised 32%-34% CD4 + and 55%-64% CD8 + T cells  of  predominately  T-effector  memory  phenotype  (CD45RA   -CCR7 -, 75%-96%) ( Table 1 ).
Effects of BRAF or MEK Inhibition on PBMC and CAR T-Cell Growth
To determine the potential forGD2-iCAR PBT to be used in combination with targeted therapies, we investigated whether drugs designed to inhibit V600-mutant BRAF or wild-type MEK affected CAR T-cell activity. We first tested whether Dab, Tram, a combination of Dab and Tram (Dab:Tram), or Vem affected CAR T-cell growth by an ATP assay and determined the IC 50 for each drug combination. A concentration range of 10 nM-150 mM, and a Dab:Tram ratio of 75:1,were chosen to cover the therapeutic plasma concentration ranges previously published for these drugs (see Supplemental Data 1, Table S1 , Supplemental Digital Content 1, http://links.lww.com/JIT/ A361 which details the drugs and drug concentrations used in this study). 17 For these assays, and those described in the following sections, we chose an in vitro model employing stimulation with anti-CD3 and anti-CD28 or 1A7 and simultaneous treatment of PBMC or CAR T cells with the BRAFi or MEKi drugs, to simulate in vivo T-cell encounters with cognate antigen-bearing cells in the presence of inhibitor drug. We also investigated the use of anti-CD3 and IL-2 prestimulation with subsequent inhibitor treatment of the proliferating cells. Consistent with previous reports, 23 Fig. 2A) . Stimulated PBMC showed a similar but nonsignificant trend towards decreased CD25 expression following BRAF or MEK inhibition. Neither PBMC or CAR T-cell viability was affected by stimulation in the presence of inhibitor drugs (Fig. 2B) .
Similar to the effects seen on CD25 expression, CAR CD8 + T-cell proliferation was inhibited when cells were stimulated in the presence of the drugs. + T cells). The key aim of CAR T-cell therapy is to generate T cells that can directly kill tumor cells. We therefore wished to assess whether the effector functions associated with CTL activity, such as degranulation and IFNg production, were also affected by BRAF or MEK inhibition. Consistent with the observations for activation and proliferation, Dab and Vem inhibited CAR CTL effector function at the highest concentration only, whereas Tram and Dab:Tram inhibited CAR CTL effector function at all concentrations, and again there was a trend towards greater inhibition for CAR T cells stimulated via the CD3/CD28 receptors rather than the GD2-iCAR receptor. Dab, Tram, and Vem were also observed to significantly inhibit PBMC effector function (Fig. 3B) . Of note, inhibition was only observed for CD107a + , IFNg + , double-positive cells (ie, cells that both degranulated and produced IFNg). The CD107a single-positive cell population was unaffected by inhibitor drugs (data not shown), and few IFNg single-positive cells were observed.
In addition, the effect of BRAF or MEK inhibition on Th1 and Th2 cytokine profiles was also assessed ( 
Effect of BRAF or MEK Inhibition on Poststimulation Ca 2 + Flux and Phosphorylation of Signaling Proteins
To further investigate the effects of these drugs on T-cell function, we assessed intracellular signaling changes upon stimulation of endogenous and CARs in the presence of inhibitor drugs. Ca 2 + flux imaging by flow cytometry revealed that the initiation of T-cell activation was not significantly affected by the presence of any of the inhibitor drugs (data not shown). However, irrespective of inhibitor use, we observed that stimulation via the CAR did not require cross-linking to produce an immediate Ca 2 + flux, whereas the Ca 2 + flux after CD3 receptor stimulation did require cross-linking.
We next assayed ERK1/2 phosphorylation, as this molecule is directly downstream of BRAF/MEK signaling, and is reported to be paradoxically activated by some BRAF inhibitors in BRAF wild-type cells. 33 We also assayed phosphorylation of AKT, a signaling molecule in a parallel pathway often upregulated in melanoma, 34 and STAT5 and STAT6, signaling molecules that are involved in T-cell-elaborated cytokine and growth factor responses, as well as in T-cell proliferation and differentiation. 35, 36 We found that phospho-ERK1/2 levels were decreased in stimulated CD8
+ CAR T cells treated with intermediate to high concentrations of Tram alone or Dab:Tram (Fig. 4A ). There was a trend towards increased pERK in Dab-treated or Vem-treated, stimulated CD8 + CAR T cells at the 
Effect of Therapeutic Concentrations of Inhibitor Drugs on T-Cell Function
The previously shown experiments suggest that BRAF and/or MEK inhibition interferes with T-cell signaling and subsequent effector functions, however, the observed inhibition may be a property of the particular in vitro culture system and the high concentrations of available drug. To better mimic an in vivo scenario, we tested the drugs at therapeutically relevant concentrations (based on those previously reported, Table S1 , Supplemental Digital Content 1, http://links.lww.com/JIT/A361) in a GD2-iCAR PBT/GD2 + tumor cell coculture assay and measured the effect on CTL activity (Fig. 5) . We found that the CAR T cells were resistant to Dab or Tram inhibition when cultured with the highly GD2 + LAN-1 neuroblastoma cell line, but were consistently inhibited by therapeutic concentrations of Vem and, for CAR T cells of patient #1, by therapeutic concentrations of Dab:Tram. For the M238 FIGURE 2. BRAF and/or MEK inhibitor treatment affect GD2-iCAR PBT activation but not viability following stimulation. Cells were cultured in the presence of a range of drug concentrations for 72 hours ± stimulation with plate-bound CD3/CD28 or 1A7 antibody. Data show mean ± SEM of pooled data for 3 individual healthy volunteer PBMC or 3 patients GD2-iCAR PBT with the assays performed in technical duplicates. A, Cellular activation was assessed by anti-CD25 staining and flow cytometry. B, Cell viability was assessed by Annexin V and DAPI staining and flow cytometry. and M238R1 cell lines, which have low (B30%-40%) and intermediate (B70%-80%) GD2 expression, respectively (Fig. S1C , Supplemental Digital Content 1, http://links.lww. com/JIT/A361), CTL activity was lower overall and was also more readily inhibited by drug treatment. For these cell lines Vem and Dab:Tram consistently inhibited CTL activity at a range of E:T ratios and Tram alone also inhibited CTL activity at some E:T ratios, particularly for patients #2 and #3, but showed less consistent inhibition. It is interesting to note that, CAR CTL activity against M238R1 cells was equivalent or lower than CTL activity against M238 parental cells, despite the resistant cell line having higher GD2 expression. We observed that the resistant cell lines upregulated the inhibitory molecule PDL1, however, this did not appear to be responsible for the lower CTL activity observed as PD1 blockade did not enhance CTL activity to the levels seen for sensitive cell lines (see Supplemental Data 1, Fig. S4 , Supplemental Digital Content 1, http://links.lww.com/JIT/ A361). Healthy donor vaccinia-specific T cells responded appropriately as a positive control for anti-PD1 mAb action (data not shown). Importantly, Dab alone did not inhibit CTL activity against any tumor cell line at therapeutic concentrations for any of the patient CAR T cells. Nontransduced control cells did not demonstrate specific killing of tumor cells and none of the CAR T cells showed specific killing of the GD2-negative cell line, SK-MEL-28, nor of autologous PHA blasts irrespective of the presence of inhibitor drugs (data not shown).
Finally, to relate the previously shown findings to more clinically relevant circumstances, we obtained pretreatment and on-treatment (after steady state drug concentrations were expected to be reached) PBMC from a metastatic melanoma patient receiving Dab/Tram combination treatment. Following ex vivo stimulation, there were decreased frequencies of CD107a/IFNg + CD8 + T cells and pSTAT5 for the ontreatment sample compared with the pretreatment sample FIGURE 3. BRAF and/or MEK inhibitor treatment affect GD2-iCAR PBT poststimulation effector functions. Results show mean ± SEM of pooled data for 3 individual healthy volunteer PBMC or 3 patients GD2-iCAR PBT, with the assay performed in technical duplicates. A, Cells were cultured in the presence of a range of drug concentrations for 72 hours ± stimulation with plate-bound CD3/CD28 or 1A7 antibody. T-cell proliferation was assessed by Ki67, anti-CD8, and anti-CD3 staining and flow cytometry. B, Cells were cultured in the presence of a range of drug concentrations for 48 hours, then transferred to uncoated or CD3/CD28 or 1A7 antibody-coated plates for 6 hours in the presence of anti-CD107a antibody and GolgiStop. Cells were then fixed, permeabilized, and stained with anti-CD3, anti-CD8, and anti-IFNg. lww.com/JIT/A361), which is more in keeping with the in vitro findings described previously. Although these data from a single patient only allow us to draw limited conclusions, the results suggest that T-cell functions were either less inhibited in the patient than they were in vitro or that the T cells had recovered after washing from drug and stimulation for 48 hours.
DISCUSSION
Selective mitogen-activated protein kinase (MAPK) pathway inhibitors may assist the immune response to melanoma by inducing immune-sensitization of the tumor, and thus be useful in combination with adoptive T-cell transfer, an approach that has found some success in mouse models. 32 ,37 Yet, given their action on universal cellular + T-cell ERK1/2 phosphorylation after culture with inhibitor drugs. B, CD8 + T-cell AKT phosphorylation after culture with inhibitor drugs. Cells were cultured in the presence of a range of drug concentrations for 72 hours ± stimulation with plate-bound CD3/CD28 or 1A7 antibody. Following stimulation and drug treatment cells were fixed, permeabilized, and stained with CD3-PE, CD8-PeCy7, pERK1/2-FITC, pAKT-bv421. Data show mean ± SEM of the pooled data for 3 individual healthy volunteers PBMC or 3 patients' GD2-iCAR PBT samples, with the assays performed in technical duplicates.
activation pathways, these inhibitors may adversely affect immune cells expressing wild-type versions of these molecules. It has been reported that Vem has no effect on unstimulated or prestimulated normal lymphocytes at a range of concentrations, 23 and likewise we found little inhibition of unstimulated PBMC or prestimulated PBMC treated with Vem, Dab, or Tram. However, we believe our method of stimulating cells in the presence of BRAF/MEK inhibition more accurately models the initiation of T-cell stimulation in treated patients. In this model, we found that all 3 drugs at the highest concentrations had clear inhibitory effects on concurrently stimulated T cells, with IC 50 values in the range of 5-80 mM depending on the drug and type of stimulation assessed (Fig. S1A , Supplemental Digital Content 1, http://links.lww.com/JIT/A361).
To further investigate the effect of BRAFi and MEKi on T-cell functions, we examined a truncated range of concentrations, chosen to include more therapeutically relevant "high," "intermediate," and "low" concentrations for each drug, and assessed their effect on activation, proliferation, and CTL effector function (Figs. 2, 3) . We found that Tram, and the combination of Dab/Tram, significantly inhibited several CAR T-cell functions across the range of in vitro concentrations, as has been recently reported by others for normal T lymphocytes, 25 and the "low" concentration in this range correspond to the higher end of the range of reported patient plasma concentrations (Table S1 , Supplemental Digital Content 1, http://links.lww.com/JIT/A361). In contrast, Dab and Vem only inhibited these functions at the high concentration of 50 mM. However, it is important to note that although this concentration is higher than the reported Dab maximum plasma concentration of B3 mM, it is within the concentration range reported for patients on Vem (86 ± 32 mM) 28 (Table S1 , Supplemental Digital Content 1, http://links.lww.com/JIT/A361). Therefore, it is possible that Vem may have a greater adverse effect than Dab on CAR Tcell function if the 2 therapies were combined in patients.
MAPK pathway inhibitor treatment variably affected phosphorylation of the signaling molecules, ERK, AKT, STAT5, and STAT6 (Fig. 4, Fig. S2 , Supplemental Digital Content 1, http://links.lww.com/JIT/A361). Tram and Dab/Tram treatment significantly reduced phosphorylation of these molecules in stimulated T cells, an effect of MEK inhibitors that has been noted previously for pERK 38 and pSTAT5. 39 To a lesser extent, Dab and Vem also decreased pAKT, pSTAT5, and pSTAT6 levels, similar to what has been reported for Vem. 23 We also found that BRAF inhibitors increased ERK phosphorylation at lower concentrations, whereas decreased pERK was observed at higher concentrations, most likely as a result of the class-specific effect of selective BRAF inhibitor-induced paradoxical MAPK pathway activation, which has been reported by others. 33 Nevertheless, we found that the proximal signaling event of intracellular calcium flux was not affected by inhibitor pretreatment. But we did find that a stronger ligation stimulus was required for an immediate Ca 2 + flux following endogenous rather than CAR stimulation. This difference may reflect quantitative differences in the activation thresholds needed for the earliest antigen receptor signaling events for these 2 receptors highlighting the differences in signaling generated by these 2 receptors (Gargett T, Brown MP. unpublished). Altogether, our results indicated that BRAF and MEK inhibition interferes with some of the downstream signaling pathways activated in response to T-cell stimulation as well in the dependent effector functions described previously.
In several of these assays we found that CAR T cells stimulated via their CAR, as opposed to stimulation with anti-CD3/CD28, appeared to be more resistant to BRAFi and MEKi treatment, further indicating differences in signaling between CAR and endogenous receptors. Several reports indicate that third-generation CARs, which include signaling domains from multiple costimulatory receptors, confer CAR T cells with improved survival, proliferation, and cytokine production compared with earlier generation CAR. 8, 40 We have directly compared stimulation via thirdgeneration CAR or CD3/CD28 in our CAR T cells and found that CAR stimulation leads to equivalent or higher levels of activation, proliferation, and effector functions, which are potentially more resistant to inhibition.
The previous investigations demonstrated inhibition of CAR T-cell function at a range of in vitro drug concentrations during direct CAR or CD3/CD28 stimulation. However, to more closely mimic a clinical scenario, we next performed CTL assays using tumor cells with a range of GD2 expression (high, intermediate, and low) and therapeutically relevant concentrations of BRAF and/or MEK inhibitor. These results confirmed that Vem clearly inhibited CAR CTL activity and Dab/Tram also inhibited CTL activity to a lesser, but still statistically significant, extent (Fig. 5) . Of note, the Dab/Tram concentration chosen was at the higher end of the patient plasma range, whereas the Vem concentration was at the lower end of the quoted patient plasma range (Table S1 , Supplemental Digital Content 1, http://links.lww.com/JIT/ A361). We observed a higher degree of inhibition of CTL activity for GD2-iCAR PBT cultured with tumor cells expressing lower GD2 levels (M238 and M238R1) than tumor cells with high GD2 expression (LAN-1). This result suggested that strong stimulation via the GD2-iCAR can overcome this inhibition of CTL function, whereas lower levels of antigen expression and CAR stimulation may make CAR T cells more susceptible to inhibition. An interesting effect observed in these experiments was that the overall CTL activity against M238R1 cells was lower than the CTL activity observed against parental M238, despite the resistant cell line having higher GD2 expression. Although we observed the upregulation of immune suppressive marker PDL1, PD1 blockade failed to enhance killing, so this reduced killing could be related to cross-resistance between CTL activity and BRAFi action in this cell line (Gargett T and Brown MP, unpublished reference). Importantly, GD2-iCAR T cells can still kill resistant cells, unlike some transgenic T cells, which reportedly cannot kill BRAFi-resistant melanoma cell lines because of cross-resistance to CTL activity. 41 Our results indicated that, like CAR T cells, PBMCderived T cells were also affected by BRAF or MEK inhibition in vitro, in particular for CD4 + T-cell proliferation, CD8 + T-cell IFNg production, and phosphorylation of some signaling molecules. Thus, these drugs appear to inhibit normal T-lymphocyte function, as well as CAR T-cell function. This was further examined in ex vivo samples from a single treated patient (Fig. S5 , Supplemental Digital Content 1, http://links.lww.com/JIT/A361), however, these preliminary results indicated that T-cell functions during Dab/Tram combination treatment in vivo may be inhibited to a much lesser extent than that observed following in vitro inhibitor treatment.
Proimmunogenic effects of selective BRAF inhibition, with or without addition of Tram, have been documented and include upregulated melanoma antigen expression, 19 reduced frequency of circulating myeloid-derived suppressor cells, 21 and increased tumor infiltration with activated CD8 + T cells. 19, 20 Immune functions were not impaired 42 nor cytokine levels 43 altered in Dab-treated melanoma patients but lymphopenia was observed in Vem -treated but not in Dab-treated patients. 44 A trial of ipilimumab and Vem was closed early due to hepatotoxicity. 45 An interim finding of severe colitis in a trial of ipilimumab with or without Dab and/or Tram in patients with metastatic melanoma (NCT01940809) prevented further recruitment to the ipilimumab and Dab/Tram arm while recruitment to the ipilimumab and Dab arm continues. 46 The latter result suggests that T-cell activity can persist in Dab/Tram-treated patients. Furthermore, these unexpected clinical findings emphasize the need for further, cautiously implemented, clinical studies of immunotherapy approaches with BRAF and MEK kinase inhibitor therapies.
We conclude that, although all the drugs tested had inhibitory effects at high concentrations, only Vem, and to a lesser extent Dab/Tram, consistently inhibited CAR Tcell functions at therapeutic-like concentrations in vitro. Unlike treatment with Tram alone, Dab/Tram, or Vem, Dab treatment at therapeutic-like concentrations preserved functional characteristics of CAR T cells post-CAR stimulation including CD25 expression, CD8 + T-cell proliferation, phosphorylation of ERK and AKT signaling molecules in CD8 + T cells, and CTL activity. Moreover, although others have shown that BRAFi-resistant melanoma cells are cross-resistant to CTL activity, 41 we have shown that GD2-iCAR PBT can still kill resistant cells albeit at a reduced level. Altogether, our results do indicate the need for further clinical investigation of immune function in patients receiving small molecule MAPK pathway inhibitor therapy.
Nonetheless, the observed variability in CTL activity of some patient's CAR T cells against GD2-expressing targets in vitro and the altogether different biological circumstances in patients may mean that a number of factors could counter inhibition of T-cell function by MAPK pathway inhibitors in vivo: increased antigen expression, an improved tumor microenvironment including modulation of HLA expression, 21 increased lymphocyte infiltration into the tumor, 19, 20 reduced effects of PDL1 blockade due to paradoxical MAPK activation in lymphocytes, 47 and by the greater range of costimulatory, cell adhesion, and chemokine and cytokine stimuli available in vivo. Support for the idea that clinically significant differences may exist in the activity of CAR T cells bathed in MAPK pathway inhibitors between in vitro and in vivo conditions is found in a recently reported preclinical study. Here, in a syngeneic murine melanoma model using therapeutic transgenic T cells specific for a melanoma antigen, combined Dab/Tram treatment inhibited transgenic T-cell function in vitro but not in vivo. 48 The evidence indicated that the superior antimelanoma activity of the adoptively transferred transgenic T cells in vivo reflected enhanced T-cell tumor infiltration, cytotoxicity, and cytokine production.
In our study, as Dab caused little or no inhibition at therapeutic-like concentrations, it may offer an alternative to Vem in combination therapy with CAR T cells, which is a proposition that we will investigate in our imminent phase I clinical trial (ACTRN12613000198729).
